164 related articles for article (PubMed ID: 35930601)
1. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
Yang F; Lin L; Li X; Wen R; Zhang X
Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
[TBL] [Abstract][Full Text] [Related]
2. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
[TBL] [Abstract][Full Text] [Related]
3. [Plasma exosomal miR-335-5p serves as a diagnostic indicator and inhibits immune escape in triple-negative breast cancer].
Chen T; Dong Y; Wu X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Apr; 38(4):347-356. PubMed ID: 35583065
[TBL] [Abstract][Full Text] [Related]
4. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Li X; Tang L; Chen Q; Cheng X; Liu Y; Wang C; Zhu C; Xu K; Gao F; Huang J; Wang R; Guan X
Chin Med J (Engl); 2022 Oct; 135(20):2436-2445. PubMed ID: 36583862
[TBL] [Abstract][Full Text] [Related]
6. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
[TBL] [Abstract][Full Text] [Related]
7. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
8. Salidroside suppresses the multiple oncogenic activates and immune escape of lung adenocarcinoma through the circ_0009624-mediated PD-L1 pathway.
Jin G; Ma M; Yang C; Zhen L; Feng M
Thorac Cancer; 2023 Aug; 14(24):2493-2503. PubMed ID: 37423604
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase 2 knockout suppresses immune escape of triple-negative breast cancer cells via downregulating PD-L1 expression.
Xu P; Xiong W; Lin Y; Fan L; Pan H; Li Y
Cell Death Dis; 2021 Aug; 12(8):779. PubMed ID: 34365463
[TBL] [Abstract][Full Text] [Related]
10. p53 downregulates PD-L1 expression via miR-34a to inhibit the growth of triple-negative breast cancer cells: a potential clinical immunotherapeutic target.
Deng S; Wang M; Wang C; Zeng Y; Qin X; Tan Y; Liang B; Cao Y
Mol Biol Rep; 2023 Jan; 50(1):577-587. PubMed ID: 36352176
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
12. eIF5B regulates the expression of PD-L1 in prostate cancer cells by interacting with Wig1.
Li Q; Xiao M; Shi Y; Hu J; Bi T; Wang C; Yan L; Li X
BMC Cancer; 2021 Sep; 21(1):1022. PubMed ID: 34525951
[TBL] [Abstract][Full Text] [Related]
13. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Aurora kinase A triggers programmed death-ligand 1-mediated immune suppression by activating MYC transcription in triple-negative breast cancer.
Sun S; Zhou W; Li X; Peng F; Yan M; Zhan Y; An F; Li X; Liu Y; Liu Q; Piao H
Cancer Commun (Lond); 2021 Sep; 41(9):851-866. PubMed ID: 34251762
[TBL] [Abstract][Full Text] [Related]
15. CircWHSC1 regulates malignancy and glycolysis by the miR-212-5p/AKT3 pathway in triple-negative breast cancer.
Ding L; Xie Z
Exp Mol Pathol; 2021 Dec; 123():104704. PubMed ID: 34624276
[TBL] [Abstract][Full Text] [Related]
16. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular PD-L1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract][Full Text] [Related]
17. PD-1 Independent Role of PD-L1 in Triple-Negative Breast Cancer Progression.
Alkaabi D; Arafat K; Sulaiman S; Al-Azawi AM; Attoub S
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047395
[TBL] [Abstract][Full Text] [Related]
18. Cancer cell-derived exosomal miR-20a-5p inhibits CD8
Li W; Han G; Li F; Bu P; Hao Y; Huang L; Bai X
Cancer Sci; 2024 Feb; 115(2):347-356. PubMed ID: 38129137
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression in triple-negative breast cancer.
Mittendorf EA; Philips AV; Meric-Bernstam F; Qiao N; Wu Y; Harrington S; Su X; Wang Y; Gonzalez-Angulo AM; Akcakanat A; Chawla A; Curran M; Hwu P; Sharma P; Litton JK; Molldrem JJ; Alatrash G
Cancer Immunol Res; 2014 Apr; 2(4):361-70. PubMed ID: 24764583
[TBL] [Abstract][Full Text] [Related]
20. Integrin α2 promotes immune escape in non-small-cell lung cancer by enhancing PD-L1 expression in exosomes to inhibit CD8 + T-cell activity.
Jing H; Meng M; Ye M; Liu S; Cao X; Li K; Liu Y; Zhang J; Wu Y
J Investig Med; 2024 Jan; 72(1):57-66. PubMed ID: 37804164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]